The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting

Coyne, Joseph W.

doi:10.6004/jadpro.2016.7.1.5

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 10 days of administration, it is eliminated by urine and feces only. Treatment with pimavanserin should be avoided for subjects with psychological disorders who have previously taken other psychotic-related drugs or any kind of antibiotic for an extended period and, thus, antibiotic interactions with pimavanserin may result in fatal diseases like cardiac arrhythmia or reduction in blood plasma levels [ 101 ].…”

Section: Therapeutic Indicationsmentioning

confidence: 99%

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

Shabir,

Saeed,

Zahid

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Fluorine is characterized by high electronegativity and small atomic size, which provide this molecule with the unique property of augmenting the potency, selectivity, metabolic stability, and pharmacokinetics of drugs. Fluorine (F) substitution has been extensively explored in drug research as a means of improving biological activity and enhancing chemical or metabolic stability. Selective F substitution onto a therapeutic or diagnostic drug candidate can enhance several pharmacokinetic and physicochemical properties such as metabolic stability and membrane permeation. The increased binding ability of fluorinated drug target proteins has also been reported in some cases. An emerging line of research on F substitution has been addressed by using 18F as a radiolabel tracer atom in the extremely sensitive methodology of positron emission tomography (PET) imaging. This review aims to report on the fluorinated drugs approved by the US Food and Drug Administration (FDA) from 2016 to 2022. It cites selected examples from a variety of therapeutic and diagnostic drugs. FDA-approved drugs in this period have a variety of heterocyclic cores, including pyrrole, pyrazole, imidazole, triazole, pyridine, pyridone, pyridazine, pyrazine, pyrimidine, triazine, purine, indole, benzimidazole, isoquinoline, and quinoline appended with either F-18 or F-19. Some fluorinated oligonucleotides were also authorized by the FDA between 2019 and 2022.

show abstract

Section: Therapeutic Indicationsmentioning

confidence: 99%

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

Shabir,

Saeed,

Zahid

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Hopelessness, Perceived Social Support and their Relationship in Iranian Patients with Cancer

Hossein

Pourmemari

Moghimi

et al. 2018

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective:Cancer is considered a global health problem and its prevalence has been growing in recent years. The present study was conducted to investigate the role of hopelessness and perceived social support for Iranian patients with cancer.Methods:Convenience sampling was used to select the study sample comprising 100 patients with cancer presenting to the Education and Treatment Center of Valiasr in Zanjan, Iran. A demographic questionnaire, the Beck Hopelessness Scale, and the Social Support from Family and Friends Scale were used to collect the data. Collected data were analyzed using SPSS-16.Results:Of the 98 study patients, 52 (53.1%) were female and the remainder were male. Lung cancer constituted the most prevalent type of cancer (25.5%). The mean hopelessness score was 5.93 ± 4.71. The mean scores for social support provided by family and friends were 10.89 ± 5.61 and 14.94 ± 4.16, respectively. Significantly negative correlations were observed between the mean scores of hopelessness and social support provided by family (P = 0.007; r = −0.270) and friends (P = 0.001; r = −0.327).Conclusion:According to the findings of the present study, Iranian patients with cancer have relatively mild levels of hopelessness and moderate levels of social support. Perceived social support was also found to affect the patients' hopefulness. Given the lack of studies on this subject, it is recommended that further studies are performed.

show abstract

An Observational Study to Evaluate the Efficacy and Quality of Life Provided by Netupitant and Palonosetron Regimen against Ondansetron in Management and Prevention of CINV

Dutta¹,

Rooha²

2021

IJPSRR

View full text Add to dashboard Cite

Cancer is a public health concern amongst millions of humans and claims hundreds of lives every year. The maximum worry-inducing side effect of cancer treatment is nausea and vomiting. Therefore, stopping and managing chemotherapy-induced nausea and vomiting is an important part of a cancer patient’s treatment plan. In this study, we evaluated the efficacy and quality of life provided by two commonly used antiemetic regimens in the management and prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. We assessed patient-reported nausea, vomiting, use of rescue medication, and Functional Living IndexEmesis (FLIE) questionnaire results, and used them as parameters to make comparisons. We also examined the percentage of patients showing complete response (CR; no emesis and non-use of rescue antiemetics), and the impact of CINV on patient’s daily life during the acute and delayed phases. The results show that the complete response is achieved by 26 patients in group-B and 18 patients in group-A, from the total 60 patients, while the FLIE scores indicated better quality of life is maintained in group-B (76.6%). In the study, the predominance of Netupitant and Palonosetron regimen to Ondansetron was demonstrated.

show abstract

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting

Cited by 3 publications

References 8 publications

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

Hopelessness, Perceived Social Support and their Relationship in Iranian Patients with Cancer

An Observational Study to Evaluate the Efficacy and Quality of Life Provided by Netupitant and Palonosetron Regimen against Ondansetron in Management and Prevention of CINV

Contact Info

Product

Resources

About